The latest news from academia, regulators
research labs and other things of interest
Posted: August 15, 2008
Companies to Develop Fluorescent Ligands to Enable Sub-100 nm Live Cell Imaging
(Nanowerk News) Promega Corporation announced that it has signed an agreement with Leica Microsystems to enable fluorescent imaging of proteins in live cells. Under the terms of the agreement, Promega will develop fluorescent ligands for its HaloTag fusion proteins, that will be used to label proteins within live cells so that they can be visualized with Leica’s TCS STED (stimulated emission depletion) superresolution microscope.
Developed in the laboratory of Dr. Stefan Hell of the Max-Planck Institute in Germany, STED microscopy enables the investigation of structural details below the 100nm range. The Leica TCS STED is the first commercially available STED light microscope and was launched in 2007.
Commonly used fluorescent proteins such as GFP are not optimal for use with high-powered STED technology as they are prone to photobleaching and lack appropriate spectral properties. In addition, alternative methods of labeling proteins with fluorescent antibodies are only applicable for fixed cells. Therefore, the agreement between Promega and Leica Microsystems will enable imaging of proteins within live cells at sub 100nm range.
“This is a perfect example of the collaborative culture within Promega,” said Dr. Georgyi Los, lead scientist for imaging products at Promega. “Leica Microsystems’ STED microscope is breaking barriers for visualizing cellular structure, creating the need for optimized reagents. Our HaloTag technology enables covalent linkage of various fluorescent dyes to proteins expressed in cells, allowing us to develop and select optimal dyes for this technology, and improving cell imaging for our customers.”
Promega has been working with Leica Microsystems since 2006 to develop novel ways to label proteins within cells using its proprietary HaloTag® technology.
Promega Corporation is a leader in providing innovative solutions and technical support to the life sciences industry. The company's 2,000 products enable scientists worldwide to advance their knowledge in genomics, proteomics, cellular analysis, molecular diagnostics and human identification. Founded in 1978, the company is headquartered in Madison, WI, USA with branches in 14 countries and over 50 global distributors. For more information about Promega, visit www.promega.com.
About Leica Microsystems
Leica Microsystems is a leading global designer and producer of innovative, high-tech, precision optical systems for the analysis of microstructures as well as a broad product portfolio for histopathology. It is one of the market leaders in the business areas Microscopy, Confocal Laser Scanning Microscopy with corresponding Imaging Systems, Specimen Preparation, and Medical Equipment. The company manufactures a broad range of products for numerous applications requiring microscopic imaging, measurement, and analysis. It also offers system solutions for life science including biotechnology and medicine, research and development of raw materials, and industrial quality assurance. Furthermore, Leica Microsystems brings histopathology labs and researchers the highest quality, most comprehensive product portfolio. The range includes the ideal product for each histology step and high-productivity workflow solutions for the entire lab, supporting better patient care through rapid turnaround, diagnostic confidence and close customer collaboration. The company with its 4,200 associates is represented in over 100 countries with 10 manufacturing facilities in 8 countries, sales and service organizations in 19 countries and an international network of dealers. The international management is headquartered in Wetzlar, Germany.